Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Pacritinib |
Trade Name | Vonjo |
Synonyms | SB1518|SB-1518|SB 1518 |
Drug Descriptions |
Vonjo (pacritinib) is an inhibitor of JAK2 and FLT3, with activity against JAK2 V617F and FLT3 ITD, which potentially increases tumor cell apoptosis, induces cell cycle arrest, and decreases tumor growth (PMID: 22829080, PMID: 21691275). Vonjo (pacritinib) is FDA approved for use in patients with primary or secondary myelofibrosis (FDA.gov). |
DrugClasses | FLT3 Inhibitor 69 JAK2 Inhibitor - ATP competitive 15 |
CAS Registry Number | 937272-79-2 |
NCIT ID | C78837 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Acalabrutinib + Pacritinib | Acalabrutinib Pacritinib | 0 | 1 |
Azacitidine + Pacritinib | Azacitidine Pacritinib | 0 | 1 |
Bemcentinib + Pacritinib | Bemcentinib Pacritinib | 0 | 1 |
Cytarabine + Daunorubicin + Pacritinib | Cytarabine Daunorubicin Pacritinib | 1 | 1 |
Cytarabine + Pacritinib | Cytarabine Pacritinib | 0 | 1 |
Decitabine + Pacritinib | Decitabine Pacritinib | 1 | 3 |
Erlotinib + Pacritinib | Erlotinib Pacritinib | 0 | 1 |
Ibrutinib + Pacritinib | Ibrutinib Pacritinib | 0 | 2 |
Pacritinib | Pacritinib | 19 | 9 |
Pacritinib + Talazoparib | Pacritinib Talazoparib | 0 | 1 |
Pacritinib + Zanubrutinib | Pacritinib Zanubrutinib | 0 | 1 |